Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Cefuroxime
Overview
What is Cefuroxime?
Cefuroxime for Injection, USP is a sterile semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R,7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2-yl) acetamido] ceph-3-em-4-carboxylate, and it has the following chemical structure:
The empirical formula is CHNNaOS, representing a molecular weight of 446.4.
Cefuroxime for Injection, USP contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.
Cefuroxime for Injection, USP in sterile crystalline form is supplied in Pharmacy Bulk Package equivalent to 7.5 g of cefuroxime as cefuroxime sodium. Solutions of Cefuroxime for Injection, USP range in color from light yellow to amber, depending on the concentration and diluent used. The pH of freshly constituted solutions usually ranges from 6 to 8.5.
A pharmacy bulk package is a container of a sterile powder for parenteral use that contains many single doses. The contents are intended for use in a pharmacy admixture service and are restricted to the preparation of admixtures for intravenous infusion. FURTHER DILUTION IS REQUIRED BEFORE USE.
What does Cefuroxime look like?
What are the available doses of Cefuroxime?
Sorry No records found.
What should I talk to my health care provider before I take Cefuroxime?
Sorry No records found
How should I use Cefuroxime?
Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases:
Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated.
In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Prevention:
Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance.
The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted.
This insert labeling is for a Pharmacy Bulk Package and is intended for preparing admixtures for intravenous infusion only.
What interacts with Cefuroxime?
Cefuroxime for Injection, USP is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.
What are the warnings of Cefuroxime?
6. Cataracts - Subcapsular bilateral cataracts occurred in 10%, and unilateral in 6.3%, of male rats treated with gemfibrozil at 10 times the human dose.
BEFORE THERAPY WITH CEFUROXIME FOR INJECTION, USP IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. IF AN ALLERGIC REACTION TO CEFUROXIME FOR INJECTION, USP OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES.
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.
When the colitis is not relieved by drug discontinuation or when it is severe, oral vancomycin is the treatment of choice for antibiotic-associated pseudomembranous colitis produced by . Other causes of colitis should also be considered.
What are the precautions of Cefuroxime?
General
Although Cefuroxime for Injection, USP rarely produces alterations in kidney function, evaluation of renal status during therapy is recommended, especially in seriously ill patients receiving the maximum doses. Cephalosporins should be given with caution to patients receiving concurrent treatment with potent diuretics as these regimens are suspected of adversely affecting renal function.
The total daily dose of Cefuroxime for Injection, USP should be reduced in patients with transient or persistent renal insufficiency (see DOSAGE AND ADMINISTRATION), because high and prolonged serum antibiotic concentrations can occur in such individuals from usual doses.
As with other antibiotics, prolonged use of Cefuroxime for Injection, USP may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.
Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins.
As with other therapeutic regimens used in the treatment of meningitis, mild-to-moderate hearing loss has been reported in a few pediatric patients treated with cefuroxime. Persistence of positive CSF (cerebrospinal fluid) cultures at 18 to 36 hours has also been noted with cefuroxime injection, as well as with other antibiotic therapies; however, the clinical relevance of this is unknown.
Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous Vitamin K administered as indicated.
Prescribing Cefuroxime for Injection, USP in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Information for Patients
Patients should be counseled that antibacterial drugs, including Cefuroxime for Injection, USP should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When Cefuroxime for Injection, USP is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by Cefuroxime for Injection, USP or other antibacterial drugs in the future.
Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.
Drug Interactions
In common with other antibiotics, cefuroxime may affect the gut flora, leading to lower estrogen reabsorption and reduce efficacy of combined estrogen/progesterone oral contraceptives.
Drug/Laboratory Test Interactions
A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedict’s or Fehling’s solution or with CLINITEST tablets) but not with enzyme-based tests for glycosuria. As a false-negative result may occur in the ferricyanide test, it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving Cefuroxime for Injection, USP.
Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime in the mouse lymphoma assay and a battery of bacterial mutation tests. Positive results were obtained in an chromosome aberration assay, however, negative results were found in an micronucleus test at doses up to 10 g/kg. Reproduction studies in mice at doses up to 3,200 mg/kg per day (3.1 times the recommended maximum human dose based on mg/m) have revealed no impairment of fertility.
Reproductive studies revealed no impairment of fertility in animals.
Pregnancy
Pregnancy Category B Reproduction studies have been performed in mice at doses up to 6,400 mg/kg per day (6.3 times the recommended maximum human dose based on mg/m) and rabbits at doses up to 400 mg/kg per day (2.1 times the recommended maximum human dose based on mg/m) and have revealed no evidence of impaired fertility or harm to the fetus due to cefuroxime. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Nursing Mothers
Since cefuroxime is excreted in human milk, caution should be exercised when Cefuroxime for Injection, USP is administered to a nursing woman.
Pediatric Use
Safety and effectiveness in pediatric patients below 3 months of age have not been established. Accumulation of other members of the cephalosporin class in newborn infants (with resulting prolongation of drug half-life) has been reported.
Geriatric Use
Of the 1,914 subjects who received cefuroxime in 24 clinical studies of Cefuroxime for Injection, USP, 901 (47%) were 65 and over while 421 (22%) were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater susceptibility of some older individuals to drug effects cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION).
What are the side effects of Cefuroxime?
Cefuroxime for Injection, USP is generally well tolerated. The most common adverse effects have been local reactions following IV administration. Other adverse reactions have been encountered only rarely.
Local Reactions:
Gastrointestinal:
Hypersensitivity Reactions:
Blood:
Hepatic:
Kidney:
Postmarketing Experience with Cefuroxime for Injection, USP Products
In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with Cefuroxime for Injection, USP and were reported spontaneously. Data are generally insufficient to allow an estimate of incidence or to establish causation.
Array
Immune System Disorders
Array
Neurologic:
Array
Non-site Specific
Cephalosporin-class Adverse Reactions
In addition to the adverse reactions listed above that have been observed in patients treated with cefuroxime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:
Array
Adverse Reactions
Several cephalosporins, including Cefuroxime for Injection, USP, have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced (see DOSAGE AND ADMINISTRATION). If seizures associated with drug therapy should occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.
Array
Altered Laboratory Tests
What should I look out for while using Cefuroxime?
Cefuroxime for Injection, USP is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.
BEFORE THERAPY WITH CEFUROXIME FOR INJECTION, USP IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. IF AN ALLERGIC REACTION TO CEFUROXIME FOR INJECTION, USP OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES.
Clostridium difficile
C. difficile.
C. difficile
C. difficile
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.
When the colitis is not relieved by drug discontinuation or when it is severe, oral vancomycin is the treatment of choice for antibiotic-associated pseudomembranous colitis produced by . Other causes of colitis should also be considered.
What might happen if I take too much Cefuroxime?
Overdosage of cephalosporins can cause cerebral irritation leading to convulsions. Serum levels of cefuroxime can be reduced by hemodialysis and peritoneal dialysis.
How should I store and handle Cefuroxime?
GEODON for Injection should be stored at 25°C (77°F); excursions permitted to 15–30°C (59–86°F) [See USP Controlled Room Temperature] in dry form. Protect from light. Following reconstitution, GEODON for Injection can be stored, when protected from light, for up to 24 hours at 15°–30°C (59°–86°F) or up to 7 days refrigerated, 2°–8°C (36°–46°F).Store Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx onlyStore Cefuroxime for Injection, USP at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature]. Protect From Light. Cefuroxime for Injection, USP is a dry, white to off-white powder supplied in vials as follows:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 7.5 grams of cefuroxime per Pharmacy Bulk Package.Product No. NDC No.305445 63323-354-45 7.5 gram vial Pharmacy Bulk Pack (Carton of 10)Also available:Cefuroxime for Injection, USP. Cefuroxime sodium equivalent to 750 mg or 1.5 grams cefuroxime per vial.Product No. NDC No.305245 63323-352-45 750 mg vial (Carton of 25)305345 63323-353-45 1.5 gram vial (Carton of 25)Vial stoppers do not contain natural rubber latex.Rx only
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
Cefuroxime has activity against a wide range of gram-positive and gram-negative organisms, and it is highly stable in the presence of beta-lactamases of certain gram-negative bacteria. The bactericidal action of cefuroxime results from inhibition of cell-wall synthesis.
Cefuroxime is usually active against the following organisms .
Staphylococcus
aureus
Staphylococcus epidermidis
Streptococcus pneumoniae;
Streptococcus pyogenes
Enterococcus faecalis
Streptococcus faecalis
Listeria monocytogenes
Citrobacter
,
Enterobacter
,
Escherichia coli,
Haemophilus influenzae
Haemophilus
parainfluenzae, Klebsiella
Klebsiella pneumoniae
Moraxella
Branhamella) catarrhalis
Morganella morganii
Proteus morganii
Neisseria gonorrhoeae
Neisseria meningitidis, Proteus
mirabilis, Providencia rettgeri
Proteus rettgeri
Salmonella
,
Shigella
NOTE: Some strains of , , and spp. have been shown by tests to be resistant to cefuroxime and other cephalosporins. and spp., spp., , and most strains of spp. and are resistant to most first- and second-generation cephalosporins.
Peptococcus
Peptostreptococcus
Clostridium
Bacteroides
Fusobacterium
NOTE: and most strains of are resistant to cefuroxime.
Non-Clinical Toxicology
Cefuroxime for Injection, USP is contraindicated in patients with known allergy to the cephalosporin group of antibiotics.BEFORE THERAPY WITH CEFUROXIME FOR INJECTION, USP IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF ALLERGY, PARTICULARLY TO DRUGS. IF AN ALLERGIC REACTION TO CEFUROXIME FOR INJECTION, USP OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES.
Clostridium difficile
C. difficile.
C. difficile
C. difficile
If CDAD is suspected or confirmed, ongoing antibiotic use not directed against may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of , and surgical evaluation should be instituted as clinically indicated.
When the colitis is not relieved by drug discontinuation or when it is severe, oral vancomycin is the treatment of choice for antibiotic-associated pseudomembranous colitis produced by . Other causes of colitis should also be considered.
In common with other antibiotics, cefuroxime may affect the gut flora, leading to lower estrogen reabsorption and reduce efficacy of combined estrogen/progesterone oral contraceptives.
Although Cefuroxime for Injection, USP rarely produces alterations in kidney function, evaluation of renal status during therapy is recommended, especially in seriously ill patients receiving the maximum doses. Cephalosporins should be given with caution to patients receiving concurrent treatment with potent diuretics as these regimens are suspected of adversely affecting renal function.
The total daily dose of Cefuroxime for Injection, USP should be reduced in patients with transient or persistent renal insufficiency (see DOSAGE AND ADMINISTRATION), because high and prolonged serum antibiotic concentrations can occur in such individuals from usual doses.
As with other antibiotics, prolonged use of Cefuroxime for Injection, USP may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.
Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins.
As with other therapeutic regimens used in the treatment of meningitis, mild-to-moderate hearing loss has been reported in a few pediatric patients treated with cefuroxime. Persistence of positive CSF (cerebrospinal fluid) cultures at 18 to 36 hours has also been noted with cefuroxime injection, as well as with other antibiotic therapies; however, the clinical relevance of this is unknown.
Cephalosporins may be associated with a fall in prothrombin activity. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. Prothrombin time should be monitored in patients at risk and exogenous Vitamin K administered as indicated.
Prescribing Cefuroxime for Injection, USP in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
Cefuroxime for Injection, USP is generally well tolerated. The most common adverse effects have been local reactions following IV administration. Other adverse reactions have been encountered only rarely.
Local Reactions:
Gastrointestinal:
Hypersensitivity Reactions:
Blood:
Hepatic:
Kidney:
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
514Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).